REVIEW article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1639065
This article is part of the Research TopicBiologics and Targeted Therapies for Autoimmune and Auto-inflammatory Dermatoses: Balancing Efficacy with Safety and ToxicityView all articles
Novel Advances on pathophysiological mechanisms, clinical manifestations, and treatment of Antiphospholipid syndrome
Provisionally accepted
Qingnan Zhu1
Xiang-Bo Qi1Shu-Wei Ren1Yu-Ye Li1
Ze-Wen Yan1Yu Sun1Yan Shi1Qing-Si Wen1Mao-Mao Wu1Da-Peng Wang1,2*- 1Dalian Medical University, Dalian, China
- 2The First Affiliated Hospital of Dalian Medical University, Dalian, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Antiphospholipid antibody syndrome (APS) is an autoimmune disorder characterized by arterial and venous thrombosis, pregnancy-related complications, and persistent antiphospholipid antibodies. These manifestations pose significant risks to patient health and reproductive outcomes. Initially regarded as a manifestation of systemic lupus erythematosus (SLE). APS exhibits a close epidemiological association with SLE, occurring at significantly higher incidence in SLE patients. The precise pathophysiological relationship between these diseases remains unclear. Nevertheless, as an independent clinical disease, research on APS pathological mechanisms continues to advance comprehensively. The publication of the "2023 ACR/EULAR antiphospholipid syndrome classification criteria" provides refined diagnostic standards. Consequently, this review synthesizes prior studies to clarify APS pathophysiological mechanisms, explore its relationship with SLE, update emerging treatments, and provide insights for clinical management.
Keywords: Antiphospholipid Syndrome, systemic lupus erythematosus, Thromboinflammation, Thrombosis, Anticoagulants
Received: 01 Jun 2025; Accepted: 30 Jul 2025.
Copyright: © 2025 Zhu, Qi, Ren, Li, Yan, Sun, Shi, Wen, Wu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Da-Peng Wang, Dalian Medical University, Dalian, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.